KNTE

2.64 USD
-0.01 (-0.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

stock is down -0.75% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 3 June’s closed higher than May.

About

Kinnate Biopharma focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors.